Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Biography  





2 Honors and awards  





3 Significant Papers  





4 References  














Jeffery W. Kelly






العربية
Беларуская
Deutsch
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Jeffery W. Kelly
Born (1960-08-23) August 23, 1960 (age 63)
Alma mater
  • State University of New York at Fredonia
  • AwardsBreakthrough Prize in Life Sciences (2022)
    Wolf Prize (2023)
    Scientific career
    Institutions
  • Jeffery W. Kelly (born August 23, 1960 in Medina, New York) is an American businessman and chemist who is on the faculty of the Scripps Research InstituteinLa Jolla, California.

    Biography

    [edit]

    Kelly received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill (1986) and performed post-doctoral research at The Rockefeller University (1986–89).[1]

    He is former Dean of Graduate Studies (2000–2008) and Vice President of Academic Affairs (2000–2006) and co-Chairman of Molecular Medicine and the Lita Annenberg Hazen Professor of Chemistry within the Skaggs Institute of Chemical Biology at The Scripps Research InstituteinLa Jolla, California. His research focuses on understanding protein folding, misfolding and aggregation and on developing both chemical and biological strategies to ameliorate diseases caused by protein misfolding and/or aggregation.[1]

    Kelly has cofounded three biotechnology companies, FoldRx Pharmaceuticals with Susan Lindquist in 2003,[2] Proteostasis Therapeutics, Inc. with Andrew Dillin and Richard Morimoto in 2010,[3] and Misfolding Diagnostics[4] in 2012.[5]

    His lab began looking for ways to inhibit transthyretin fibril formation in the 1990s.[6]: 210  Tafamidis was eventually discovered by Kelly's team using a structure-based drug design strategy; the structure was first published in 2003.[7][2] In 2003 Kelly co-founded FoldRx with Susan Lindquist of MIT and the Whitehead Institute[2][8] and FoldRx developed tafamidis up through submitting an application for marketing approval in Europe in early 2010.[7] FoldRx was acquired by Pfizer later that year.[7]

    Honors and awards

    [edit]

    1991 - Searle Scholar Award[1]

    1999 - Biophysical Society National Lecturer (Award)

    1999 - Protein Society-Dupont Young Investigator Award

    2000 - SUNY at Fredonia Alumni Distinguished Achievement Award

    2001 - American Chemical Society Arthur C. Cope Scholar Award

    2006 - National Institutes of Health Merit Award

    2008 - American Peptide Society Vincent du Vigneaud Award

    2011 - American Peptide Society Rao Makineni Lectureship (Award)

    2011 - Protein Society Emil T. Kaiser Award

    2012 - American Chemical Society, Ralph F. Hirschmann Award in Peptide Chemistry

    2012 - the Biopolymers Murray Goodman Memorial Prize

    2016 - Royal Society of Chemistry Jeremy Knowles Award

    2016 - Jacob Heskel Gabbay Award in Biotechnology and Medicine

    2016 - Commencement address at SUNY Fredonia.[9]

    2016 - Member of the American Academy of Arts and Sciences

    2017 - Chemical Pioneer Award of the American Institute of Chemists

    2017 - Fellow of the Royal Society of Chemistry

    2017 - Fellow of the National Academy of Inventors

    2022 - Breakthrough Prize in Life Sciences

    2023 - Wolf Prize in Chemistry[10]

    Significant Papers

    [edit]

    1992 Colon, W.; Kelly, J.W. "Partial Denaturation of Transthyretin is Sufficient for Amyloid Fibril Formation In Vitro." Biochemistry, 31 8654-8660.

    2001 Jager, M.; Nguyen, H.; Crane, J.C.; Kelly, J.W.; Gruebele, M.『The Folding Mechanism of a β-Sheet: The WW Domain』J. Mol. Biol., 311, 373-393.

    2001 Hammarstrom, P.; Schneider, F.; Kelly, J.W. "Trans-Suppression of Misfolding In An Amyloid Disease" Science 293, 2459-2461.

    2002 Sawkar, A.R.; Cheng, W-C.; Beutler, E.: Wong, C.–H.: Balch, W.E.: Kelly, J.W.『Chemical Chaperones Increase the Cellular Activity of N370S β-glucosidase: A Therapeutic Strategy for Gaucher Disease 』 Proc. Natl. Acad. Sci. 99, 15428-15433.

    2003 Hammarstrom, P.; Wiseman, R. L.; Powers, E.T.; Kelly, J.W. "Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics" Science 299, 713-716.

    2004 Deechongkit, S.; Nguyen, H.; Dawson, P.E.; Gruebele, M.; Kelly, J.W. “Context Dependent Contributions of Backbone H-Bonding to β-Sheet Folding Energetics” Nature 430, 101-105.

    2005 Sekijima, Y., Wiseman, R.L., Matteson, J., Hammarström, P., Miller,S.R., Balch, W.E., Kelly, J.W. “Biological and Chemical Basis for Tissue Selective Amyloid Disease”Cell 121, 73-85.

    2006 Fowler, D.M.; Koulov, A.V.; Alory-Jost, C.; Marks, M.S.; Balch, W.E; Kelly, J.W. "Functional Amyloid Formation Within Mammalian Tissue " PLoS Biology 4, 100-107.

    2008 Mu, T-W.; Ong, D.S.T.; Wang, Y-J; Balch, W. E.; Yates, J.R.; Segatori, L.; Kelly, J.W. .”Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases” Cell 134, 769-781.

    2008 Balch, W.E.; Morimoto, R.I.; Dillin, A.; Kelly, J.W. “Adapting Proteostasis For Disease Intervention” Science 319, 916-919.

    2010 Wiley; died in a car crash

    2011 Culyba, E.K.; Price, J.L.; Hanson, S.R.; Dhar, A,; Wong, C-H.; Gruebele, M.; Powers, E.T.; Kelly, J.W. “Protein Native State Stabilization by Placing Aromatic Side Chains in N-Glycosylated Reverse Turns” Science 331, 571-575.

    2012 Bulawa, C.E.; Connelly, S.; DeVit, M.; Wang, L. Weigel, C.;Fleming, J. Packman, J.; Powers, E.T.; Wiseman, R.L.; Foss, T.R.; Wilson, I.A.; Kelly, J.W.; Labaudiniere, R. “Tafamidis, A Potent and Selective Transthyretin Kinetic Stabilizer That Inhibits the Amyloid Cascade” Proc. Natl. Acad. Sci. 109, 9629-9634.

    2013 Chen, W; Enck, S.; Price, J.L.; Powers, D.L.; Powers, E.T.; Wong, C-H.; Dyson, H.J.; Kelly, J.W. “The Structural and Energetic Basis of Protein-Carbohydrate Interactions” J. Am. Chem. Soc. 135, 9877-9884.

    References

    [edit]
    1. ^ a b c Faculty biography, Scripps, Retrieved April 2, 2018
  • ^ a b c Borman, Stu (January 25, 2010). "Attacking Amyloids". Chemical & Engineering News. 88 (4): 30–32. doi:10.1021/cen-v088n004.p030.
  • ^ Timmerman, Luke (May 3, 2010). "Proteostasis, with San Diego Roots and Boston Home, Seeks Edge in Alzheimer's and Parkinson's". Xconomy.
  • ^ "Form S-1". Proteostasis Therapeutics via SEC Edgar. December 23, 2015.
  • ^ Preston, Juliet (February 5, 2013). "J&J Creates Space at Janssen Labs for Life Sciences Entrepreneurs". Xconomy.
  • ^ Labaudiniere, Richard (2014). "Chapter 9: Discovery and Development of Tafamidis for the Treatment of TTR Familial Amyloid Polyneuropathy". In Pryde, David C; Palmer, Michael J (eds.). Orphan Drugs and Rare Diseases. RSC Drug Discovery Series No. 38. Royal Society of Chemistry. ISBN 978-1-84973-806-4.
  • ^ a b c Jones, Dan (October 29, 2010). "Modifying protein misfolding". Nature Reviews Drug Discovery. 9 (11): 825–827. doi:10.1038/nrd3316.
  • ^ Breznitz, Shiri M.; O'Shea, Rory P.; Allen, Thomas J. (March 2008). "University Commercialization Strategies in the Development of Regional Bioclusters". Journal of Product Innovation Management. 25 (2): 129–142. doi:10.1111/j.1540-5885.2008.00290.x.
  • ^ see Commencement address at: youtu.be/4YA7btif6A8
  • ^ Wolf Prize in Chemistry 2023

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Jeffery_W._Kelly&oldid=1217694899"

    Categories: 
    1960 births
    Living people
    21st-century American businesspeople
    21st-century American chemists
    American chemical industry businesspeople
    Businesspeople from New York (state)
    Businesspeople in the pharmaceutical industry
    American organic chemists
    People from Medina, New York
    Scripps Research faculty
    Scientists from New York (state)
    Wolf Prize in Chemistry laureates
    Hidden categories: 
    Articles with short description
    Short description is different from Wikidata
    Use mdy dates from March 2024
    Articles with hCards
    Articles with ISNI identifiers
    Articles with VIAF identifiers
    Articles with WorldCat Entities identifiers
    Articles with BNF identifiers
    Articles with BNFdata identifiers
    Articles with GND identifiers
    Articles with J9U identifiers
    Articles with KBR identifiers
    Articles with LCCN identifiers
    Articles with NKC identifiers
    Articles with ORCID identifiers
    Articles with SUDOC identifiers
     



    This page was last edited on 7 April 2024, at 09:41 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki